Literature DB >> 23827161

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Mehmet Coskun1, Mohammad Salem, Jannie Pedersen, Ole Haagen Nielsen.   

Abstract

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway constitute the fulcrum in many vital cellular processes, including cell growth, differentiation, proliferation, and regulatory immune functions. Various cytokines, growth factors, and protein tyrosine kinases communicate through the JAK/STAT pathway and regulate the transcription of numerous genes. In addition to their critical roles in a plethora of key cellular activities, the JAK/STAT signaling pathways also have been implicated in the pathogenesis of several diseases, including inflammatory bowel disease (IBD), especially since a JAK inhibitor recently has been shown to be effective in the treatment of ulcerative colitis. The aim of this review is to highlight the recent findings on the regulatory mechanism of JAK/STAT signaling pathways and to reveal the evolving comprehension of their interface which might be of interest for clinicians involved in IBD therapy. Further, it is described how these signaling pathways have been exploited for the development of promising novel JAK inhibitors with anti-inflammatory effects verified in clinical trials.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD; Crohn's disease; DSS; IBD; IEC; IFN; IL; Inflammatory bowel disease; JAK; Janus kinase; LDL; RA; ROR; STAT; T helper; TNF; TYK; Th; Tofacitinib; Treg; UC; Ulcerative colitis; dextran sodium sulfate; inflammatory bowel disease; interferon; interleukin; intestinal epithelial cell; low-density lipoprotein; regulatory T; retinoid-related orphan receptor; rheumatoid arthritis; signal transducer and activator of transcription; tumor necrosis factor; tyrosine kinase; ulcerative colitis

Mesh:

Substances:

Year:  2013        PMID: 23827161     DOI: 10.1016/j.phrs.2013.06.007

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  88 in total

Review 1.  Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.

Authors:  Aurelien Amiot; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 2.  Pathway-based approaches to the treatment of inflammatory bowel disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Transl Res       Date:  2015-09-07       Impact factor: 7.012

Review 3.  Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin?

Authors:  Mariabeatrice Principi; Floriana Giorgio; Giuseppe Losurdo; Viviana Neve; Antonella Contaldo; Alfredo Di Leo; Enzo Ierardi
Journal:  World J Gastrointest Pathophysiol       Date:  2013-11-15

Review 4.  Emerging biologics in inflammatory bowel disease.

Authors:  Heyson Chi-Hey Chan; Siew Chien Ng
Journal:  J Gastroenterol       Date:  2016-11-10       Impact factor: 7.527

5.  Unraveling the Control of Cell Cycle Periods during Intestinal Stem Cell Differentiation.

Authors:  Richard Ballweg; Suengwon Lee; Xiaonan Han; Philip K Maini; Helen Byrne; Christian I Hong; Tongli Zhang
Journal:  Biophys J       Date:  2018-11-03       Impact factor: 4.033

Review 6.  A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.

Authors:  Kenechukwu O Chudy-Onwugaje; Kaci E Christian; Francis A Farraye; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

Review 7.  When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.

Authors:  Suneeta Krishnareddy; Arun Swaminath
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 8.  Animal models of inflammatory bowel disease: a review.

Authors:  Nidhi Goyal; Ajay Rana; Abhilasha Ahlawat; Krishna Reddy V Bijjem; Puneet Kumar
Journal:  Inflammopharmacology       Date:  2014-06-07       Impact factor: 4.473

9.  Red wine polyphenol extract efficiently protects intestinal epithelial cells from inflammation via opposite modulation of JAK/STAT and Nrf2 pathways.

Authors:  Carla Nunes; Natércia Teixeira; Diana Serra; Víctor Freitas; Leonor Almeida; João Laranjinha
Journal:  Toxicol Res (Camb)       Date:  2015-10-05       Impact factor: 3.524

10.  Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.

Authors:  Iris Dotan; Etgar Levy-Nissenbaum; Yehuda Chowers; Alexander Fich; Eran Israeli; Tomer Adar; Shimon Shteingart; Hermona Soreq; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-08-29       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.